Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function

Phase 1 Completed 24 enrolled AstraZeneca

Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to assess the pharmacokinetics of NKTR-118 in patients with impaired hepatic function versus subjects with normal hepatic function.

Timeline

Start: 2011-07
Primary completion: 2011-11
Completion: 2011-11

Publications

Bui K, She F, Sostek M. The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol. J Clin Pharmacol. 2014 Dec;54(12):1368-74. doi: 10.1002/jcph.348. Epub 2014 Jun 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Naloxegol	Small molecule	25 mg	Oral

Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function

Summary

Timeline

Publications

Drugs

Indications